The University of Texas MD Anderson Cancer Center

This is your central portal for breaking news, the latest research and important updates from The University of Texas MD Anderson Cancer Center. Bookmark this page and check back often for updates.

Meeting News

Encorafenib regimens confer quality-of-life benefit in BRAF V600E-mutant metastatic colorectal cancer

January 23, 2020
A combination of encorafenib and cetuximab, with or without binimetinib, demonstrated significant improvement in patient-reported quality-of-life…
FDA News

FDA grants orphan drug designation to OBI-999 for gastric cancer

January 23, 2020
The FDA granted orphan drug designation to the antibody-drug conjugate OBI-999 for the treatment of gastric cancer, according to the agent’s…
Point/Counter

Should gemcitabine plus nab-paclitaxel be used in the adjuvant pancreatic cancer setting?

HemOnc Today, January 10, 2020
The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to…

$1 million grants fund research into melanoma metastasis

January 4, 2020
American Cancer Society and Melanoma Research Alliance provided two $1 million grants that will fund research focused on metastasis of melanoma and…
In the Journals

Multidisciplinary clinics may improve prostate cancer care

January 2, 2020
Men with prostate cancer who sought treatment at a multidisciplinary clinic appeared more likely to receive advice about treatment choices and care…
Meeting NewsPerspective

Polyfunctional strength index identifies responders to combination immunotherapy in acute myeloid leukemia

December 26, 2019
ORLANDO — Polyfunctional strength index on pretherapy bone marrow CD4-positive T cells differed substantially between responders and…
FDA News

FDA grants breakthrough therapy designation to tucatinib for advanced breast cancer

December 18, 2019
The FDA granted breakthrough therapy designation to tucatinib in combination with trastuzumab and capecitabine for the treatment of locally advanced…
Meeting News

Venetoclax plus ibrutinib linked to high likelihood of undetectable minimal residual disease in CLL

December 16, 2019
ORLANDO — The addition of venetoclax to ibrutinib as a consolidation therapy appeared associated with high rates of undetectable minimal…
Meeting NewsPerspective

Complete response, minimal residual disease negativity linked to lower relapse risk in relapsed/refractory AML

December 14, 2019
ORLANDO — Achieving complete remission and minimal residual disease negativity appeared to be independently associated with reduced cumulative…
Meeting NewsPerspective

Residual cancer burden predicts long-term outcomes across breast cancer subtypes

December 13, 2019
SAN ANTONIO — Residual cancer burden after neoadjuvant chemotherapy accurately predicted long-term recurrence risk and survival across all…
Meeting NewsPerspective

Tucatinib regimen provides ‘unprecedented’ benefit in heavily pretreated HER2-positive breast cancer

December 11, 2019
SAN ANTONIO — The addition of tucatinib to trastuzumab and capecitabine significantly extended survival among heavily pretreated patients with…
Cover Story

Harnessing the gut to improve cancer outcomes

HemOnc Today, December 10, 2019
The gut microbiome — made up of more than a trillion microbes, archaea, viruses, phages, yeast, fungi and bacteria in the intestine — has…
Meeting News

Genetic biomarkers predict long-term OS for adoptive cell therapy in metastatic melanoma

November 22, 2019
NATIONAL HARBOR, Md. — Certain genetic biomarkers predicted long-term overall survival for patients who received adoptive cell therapy with…
Meeting News

‘Stay tuned:’ Neoadjuvant therapy in thyroid cancer still needs research

November 19, 2019
CHICAGO — There are many targeted agents being tested in the neoadjuvant setting for thyroid cancer, however, it is important to understand the…
FDA News

FDA approves Brukinsa for relapsed or refractory mantle cell lymphoma

November 14, 2019
The FDA granted accelerated approval to zanubrutinib for use by adults with previously treated mantle cell lymphoma. Zanubrutinib (Brukinsa, BeiGene)…
In the JournalsPerspective

Secondary surgery does not prolong survival in recurrent ovarian cancer

November 13, 2019
Secondary surgical cytoreduction followed by chemotherapy did not extend OS compared with chemotherapy alone among women with platinum-sensitive…
Meeting News

Sitravatinib plus nivolumab safe, active in advanced urothelial carcinoma

November 13, 2019
NATIONAL HARBOR, Md. — The combination of sitravatinib and nivolumab induced encouraging clinical activity among patients with advanced…
In the JournalsPerspective

Symptom burden a key component of disease control assessment in polycythemia vera

November 8, 2019
Patients with polycythemia vera can experience high symptom burden even if their blood counts are controlled, according to an analysis from the…

Oncology societies praise nomination of radiation oncologist for FDA commissioner

November 1, 2019
Several oncology societies today praised President Donald J. Trump’s nomination of Stephen M. Hahn, MD, to be the next FDA commissioner. Hahn…
Trend Watch

MD Anderson, Ziopharm renew R&D agreement to include T-cell receptor-based therapies

October 31, 2019
The University of Texas MD Anderson Cancer Center has announced a new research and development agreement with partner Ziopharm Oncology for the…